A phase II trial of monalizumab as signle agent in recurrent or metastatic head and neck cancer
Latest Information Update: 26 Sep 2016
Price :
$35 *
At a glance
- Drugs Monalizumab (Primary)
- Indications Head and neck cancer
- Focus Therapeutic Use
- 26 Sep 2016 New trial record